Key statistics
On Monday, Sagimet Biosciences Inc (0O2:FRA) closed at 2.86, 30.00% above the 52 week low of 2.20 set on Aug 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.78 |
---|---|
High | 2.86 |
Low | 2.78 |
Bid | 2.52 |
Offer | 2.62 |
Previous close | 2.92 |
Average volume | 42.86 |
---|---|
Shares outstanding | 32.20m |
Free float | 26.35m |
P/E (TTM) | -- |
Market cap | 101.09m USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 14:29 BST.
More ▼
Announcements
- Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
- Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
- Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
- Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat
- Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
- Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
- Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
- Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
More ▼